Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: A randomized double-blinded trial

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 6, 2013, Pages 794-801

  Lin, Z P ^a   Dong, M ^b   Liu, J ^b  

^a Sun Yat sen Cardiovascular Hospital   (China)

^b Shenzhen University   (China)

Author keywords

Bisoprolol; Endothelial function; Hypertension; Stable angina; Survival of myocardium

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART MUSCLE; HEART MUSCLE PERFUSION; HEART VENTRICULOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TREATMENT DURATION; VASCULAR ENDOTHELIUM;

ANGINA, STABLE; BISOPROLOL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEART; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 84878546544     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. BAGUET JP, BARONE-ROCHETTE G, MALLION JM. European Society of Hypertension Scientific Newsletter: Hypertension and coronary heart disease. J Hypertens 2006; 24: 2323-2325.
2. MACMAHON S, PETO R, CUTLER J, COLLINS R, SORLIE P, NEATON J, ABBOTT R, GODWIN J, DYER A, STAMLER J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
3. RUTAN GH, KULLER LH, NEATON JD, WENTWORTH DN, MCDONALD RH, SMITH WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 1988; 77: 504-514.
4. ERCAN E, TENGIZ I, ERCAN HE, NALBANTGIL I. Left ventricular hypertrophy and endothelial functions in patients with essential hypertension. Coron Artery Dis 2003; 14: 541-544.
5. CELERMAJER DS, SORENSEN KE, GOOCH VM, NALBANTGIL I. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
6. MATERSON BJ, REDA DJ, CUSHMAN WC, MASSIE BM, FREIS ED, KOCHAR MS, HAMBURGER RJ, FYE C, LAKSHMAN R, GOTTDIENER J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921.
7. LANDS AM, ARNOLD A, MCAULIFF JP, LUDUENA FP, BROWN TG JR. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597-598.
8. ITO M, FUKUDA N, IZUMI Y, WATANABE Y, WATANABE M, SOMA M, KANMATSUSE K. Enhancement effect of carteolol on the clonidine-induced vasodilation of rat mesenteric arteries. Pharmacol Res 1995; 31: 319-323.
9. JANSSENS WJ, VAN DE WATER A, XHONNEUX R, RENEMAN RS, VAN NUETEN JM, JANSSEN PA. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989; 159: 89-95.
10. BAKER JG, HILL SJ, SUMMERS RJ. Evolution of betablockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32: 227-234.
11. CHANNARAYA V, MARYA RK, SOMASUNDARAM M, MITRA D, TIBREWALA KD; ON THE BEHALF OF BRIGHT INVESTIGATORS. Efficacy and tolerability of a beta-1 selective beta blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open 2012; 2(3). pii: e000683.
12. NUTTALL SL, ROUTLEDGE HC, KENDALL MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther 2003; 28: 179-186.
13. NISHIO M, SAKATA Y, MANO T, OHTANI T, TAKEDA Y, MIWA T, HORI M, MASUYAMA T, KONDO T, YAMAMOTO K. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008; 10: 446-453.
14. CORRETTI MC, ANDERSON TJ, BENJAMIN EJ, CELERMAJER D, CHARBONNEAU F, CREAGER MA, DEANFIELD J, DREXLER H, GERHARD-HERMAN M, HERRINGTON D, VALLANCE P, VI TA J, VOGEL R; INTERNATIONAL BRACHIAL ARTERY REACTIVITY TASK FORCE. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
15. KANNEL WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571-1576.
16. FRANKLIN SS, KHAN SA, WONG ND, LARSON MG, LEVY D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354-360.
17. VERDECCHIA P, PORCELLATI C, SCHILLACI G, BORGIONI C, CIUCCI A, BATTISTELLI M, GUERRIERI M, GATTESCHI C, ZAMPI I, SANTUCCI A. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
18. BLACK HR, GREENBERG BH, WEBER MA. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. Am J Med 123: S2.
19. BRODDE OE. Bisoprolol (EMD 33512), a highly elective beta 1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol 1986; 8(Suppl 11): S29-35.
20. LAMMERS JW, FOLGERING HT, VAN HERWAARDEN CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S69-73.
21. KJEKSHUS JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-49F.
22. CUCHERAT M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28: 3012-3019.
23. BLACK A, MURRAY L, CARDWELL C, SMITH G-D, MCCARRON P. Secular trends in hear t rate in young adults, 1949 to 2004: analyses of cross sectional studies. Heart 2006; 92: 468-473.
24. FOX K, FORD I, STEG P-G, TENDERA M, ROBERTSON M, FERRARI R; BEAUTIFUL INVESTIGATORS. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821.
25. BOLAD I, DELAFONTAINE P. Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol. 2005; 20: 270-274.
26. GEORGESCU A, PLUTEANU F, FLONTA ML, BADILA E, DOROBANTU M, POPOV D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508: 159-166.
27. COCKCROFT JR, CHOWIENCZYK PJ, BENJAMIN N, RITTER JM. Preserved endothelium-dependent vasodilatation n patients with essential hypertension. N Engl J Med 1994; 330: 1036-1040.
28. ARRIBAS S, MARIN J, PONTE A, BALFAGÓN G, SALAICES M. Norepinephrine-induced relaxations in rat aorta mediated by endothelial beta adrenoceptors.Impairment by ageing and hypertension. J Pharmacol Exp Ther 1994; 270: 520-527.
29. BARBATO E. Role of adrenergic receptors in human coronary vasomotion. Heart 2009; 95: 603-608.
30. SIMOVA II, TODOROVA-KONSTANTINOVA RR, DENCHEV SV. Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients. Exp Clin Cardiol 2009; 14: 45-49.